Goodsurance

Drug prices & Part D

CMS Proposes Making Medicare Drug Price Negotiations a Permanent Federal Regulation

A proposed rule published June 16, 2026, would replace the program's expiring guidance authority with binding regulation covering negotiations starting with the 2029 price year.

By the Goodsurance editorial teamJuly 8, 2026

The Centers for Medicare and Medicaid Services published proposed rule CMS-4215-P in the Federal Register on June 16, 2026, to establish a durable regulatory framework for Medicare's drug price negotiation program. The proposal covers initial price applicability year 2029 and every cycle thereafter.

The Inflation Reduction Act of 2022 created the negotiation program and authorized CMS to operate the first three cycles, with prices taking effect in 2026, 2027, and 2028, through administrative guidance rather than formal rulemaking. That authority expires after the 2028 cycle.

CMS-4215-P would codify each phase of the program: drug selection and ranking, manufacturer agreement requirements, the offer-and-counteroffer process, renegotiation criteria, and publication of maximum fair prices.

The third negotiation cycle, covering 15 drugs with prices effective January 1, 2028, is currently under way. All 15 manufacturers chose to participate.

The comment period closes August 17, 2026. Comments may be submitted at regulations.gov. CMS expects to finalize the rule in fall 2026 in time to govern the 2029 cycle.

In plain words

Medicare can negotiate prices on some expensive drugs because of a 2022 law. Until now the rules for how this works came from CMS instructions, not formal regulations. That was what the law allowed for the first three rounds of talks, which cover prices through 2028. Now CMS wants to make those rules permanent. It published a proposed regulation in June 2026. The new rule would explain how CMS picks drugs, how talks with drug companies work, and how final prices are set. It would apply starting in 2029. Anyone can send comments to the government until August 17, 2026.

Source: Federal Register
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

August 4, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026